Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 66% Improvement Relative Risk Hospitalization 29% ARDS 68% Ghany et al. Metformin for COVID-19 Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? Retrospective 1,139 patients in the USA Lower mortality (p=0.00021) and hospitalization (p=0.0076) Ghany et al., Diabetes & Metabolic Syndrome: Cli.., doi:10.1016/j.dsx.2021.02.022 Favors metformin Favors control

Metformin is associated with lower hospitalizations, mortality and severe coronavirus infection among elderly medicare minority patients in 8 states in USA

Ghany et al., Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2021.02.022
Ghany et al., Metformin is associated with lower hospitalizations, mortality and severe coronavirus infection among elderly.., Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2021.02.022
Mar 2021   Source   PDF  
  All Studies   Meta
Retrospective 1,139 elderly COVID+ patients in the USA, 392 with pre-existing metformin use, showing significantly lower mortality, hospitalization, and ARDS with treatment.
risk of death, 66.0% lower, HR 0.34, p < 0.001, treatment 392, control 747, adjusted per study, multivariable, Cox proportional hazards.
risk of hospitalization, 29.0% lower, HR 0.71, p = 0.008, treatment 392, control 747, adjusted per study, multivariable, Cox proportional hazards.
risk of ARDS, 68.0% lower, HR 0.32, p < 0.001, treatment 392, control 747, adjusted per study, multivariable, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ghany et al., 31 Mar 2021, retrospective, USA, peer-reviewed, 8 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Metformin is associated with lower hospitalizations, mortality and severe coronavirus infection among elderly medicare minority patients in 8 states in USA
Reyan Ghany, Ana Palacio, Elissa Dawkins, Gordon Chen, Daniel Mccarter, Emancia Forbes, Brian Chung, Leonardo Tamariz
Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2021.02.022
Background and aims: Metformin has antiviral and anti-inflammatory effects and several cohort studies have shown that metformin lower mortality in the COVID population in a majority white population. There is no data documenting the effect of metformin taken as an outpatient on COVID-19 related hospitalizations. Our aim was to evaluate if metformin decreases hospitalization and severe COVID-19 among minority Medicare patients who acquired the SARS-CoV2 virus. Methods: We conducted a retrospective cohort study including elderly minority Medicare COVID-19 patients across eight states. We collected data from the inpatient and outpatient electronic health records, demographic data, as well as clinical and echocardiographic data. We classified those using metformin as those patients who had a pharmacy claim for metformin and non-metformin users as those who were diabetics and did not use metformin as well as non-diabetic patients. Our primary outcome was hospitalization. Our secondary outcomes were mortality and acute respiratory distress syndrome (ARDS). Results: We identified 1139 COVID-19 positive patients of whom 392 were metformin users. Metformin users had a higher comorbidity score than non-metformin users (p < 0.01). The adjusted relative hazard (RH) of those hospitalized for metformin users was 0.71; 95% CI 0.52e0.86. The RH of death for metformin users was 0.34; 95% CI 0.19e0.59. The RH of ARDS for metformin users was 0.32; 95% CI 0.22 e0.45. Metformin users on 1000 mg daily had lower mortality, but similar hospitalization and ARDS rates when compared to those on 500e850 mg of metformin daily. Conclusions: Metformin is associated with lower hospitalization, mortality and ARDS among a minority COVID-19 population. Future randomized trials should confirm this finding and evaluate for a causative effect of the drug preventing disease.
Disclosures No conflicts of interest. Credit author statement Conceptualization: Ghany
Barzilai, Crandall, Kritchevsky, Espeland, Metformin as a tool to target aging, Cell Metabol
Beigel, Tomashek, Dodd, Remdesivir for the treatment of covid-19 -preliminary report, N Engl J Med, doi:10.1056/NEJMoa2007764
Bramante, Ingraham, Murray, Observational study of metformin and risk of mortality in patients hospitalized with covid-19, Lancet Healthy Longev, doi:10.1016/S2666-7568(20)30033-7
Cheng, Liu, Li, Metformin is associated with higher incidence of acidosis, but not mortality, in individuals with COVID-19 and pre-existing type 2 diabetes, Cell Metabol
Crouse, Grimes, Li, Might, Ovalle et al., Metformin use is associated with reduced mortality in a diverse population with covid-19 and diabetes, Front Endocrinol, doi:10.3389/fendo.2020.600439
Do, Kim, Park, Cho, Kang, Is there an association between metformin use and clinical outcomes in diabetes patients with COVID-19?, Diabetes Metab, doi:10.1016/j.diabet.2020.10.006
Gandhi, Lynch, Rio, Mild or moderate covid-19, N Engl J Med, doi:10.1056/NEJMcp2009249
Gao, Liu, Zhong, Risk of metformin in patients with type 2 diabetes with COVID-19: a preliminary retrospective report, Clin Transl Sci, doi:10.1111/cts.12897
Ghany, Palacio, Dawkins, Diabetes & Metabolic Syndrome, Clinical Research & Reviews
Ghany, Tamariz, Chen, High-touch care leads to better outcomes and lower costs in a senior population, Am J Manag Care
Hariyanto, Kurniawan, Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection, Obes Med, doi:10.1016/j.obmed.2020.100290
Kulkarni, Gubbi, Barzilai, Benefits of metformin in attenuating the hallmarks of aging, Cell Metabol
Luo, Qiu, Liu, Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis, Am J Trop Med Hyg, doi:10.4269/ajtmh.20-0375
Pathak, Salunke, Thivari, No benefit of hydroxychloroquine in COVID-19: results of systematic review and meta-analysis of randomized controlled trials, Diabetes Metab Syndr
Scheen, Metformin and COVID-19: from cellular mechanisms to reduced mortality, Diabetes Metab, doi:10.1016/j.diabet.2020.07.006
Shang, Zhang, Leng, Assessment of diabetic cardiomyopathy by cardiovascular magnetic resonance T1 mapping: correlation with leftventricular diastolic dysfunction and diabetic duration, J Diabet Res, doi:10.1155/2017/9584278
Sharabiani, Aylin, Bottle, Systematic review of comorbidity indices for administrative data, Med Care, doi:10.1097/MLR.0b013e31825f64d0
Singh, Singh, Suhail, AMP-activated protein kinase restricts zika virus replication in endothelial cells by potentiating innate antiviral responses and inhibiting glycolysis, J Immunol, doi:10.4049/jimmunol.1901310
Valencia, Palacio, Tamariz, Florez, Metformin and ageing: improving ageing outcomes beyond glycaemic control, Diabetologia, doi:10.1007/s00125-017-4349-5
Zhang, Dong, Martin, AMP-activated protein kinase phosphorylation of angiotensin-converting enzyme 2 in endothelium mitigates pulmonary hypertension, Am J Respir Crit Care Med, doi:10.1164/rccm.201712-2570OC
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop